| Literature DB >> 33400911 |
Jennyfer Levoux1, Alexandre Prola2, Peggy Lafuste1, Marianne Gervais1, Nathalie Chevallier3, Zeynab Koumaiha1, Kaouthar Kefi1, Laura Braud1, Alain Schmitt4, Azzedine Yacia4, Aurélie Schirmann1, Barbara Hersant5, Mounia Sid-Ahmed5, Sabrina Ben Larbi6, Katerina Komrskova7, Jakub Rohlena8, Frederic Relaix9, Jiri Neuzil10, Anne-Marie Rodriguez11.
Abstract
Platelets are known to enhance the wound-healing activity of mesenchymal stem cells (MSCs). However, the mechanism by which platelets improve the therapeutic potential of MSCs has not been elucidated. Here, we provide evidence that, upon their activation, platelets transfer respiratory-competent mitochondria to MSCs primarily via dynamin-dependent clathrin-mediated endocytosis. We found that this process enhances the therapeutic efficacy of MSCs following their engraftment in several mouse models of tissue injury, including full-thickness cutaneous wound and dystrophic skeletal muscle. By combining in vitro and in vivo experiments, we demonstrate that platelet-derived mitochondria promote the pro-angiogenic activity of MSCs via their metabolic remodeling. Notably, we show that activation of the de novo fatty acid synthesis pathway is required for increased secretion of pro-angiogenic factors by platelet-preconditioned MSCs. These results reveal a new mechanism by which platelets potentiate MSC properties and underline the importance of testing platelet mitochondria quality prior to their clinical use.Entities:
Keywords: angiogenesis; cell therapy; citrate; de novo; fatty acid synthesis; intercellular mitochondria transfer; mesenchymal stem cells; metabolism reprogramming; mitochondria; mitochondrial respiration; platelets
Year: 2021 PMID: 33400911 DOI: 10.1016/j.cmet.2020.12.006
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287